Why Should You Attend:
The FDA issued the latest updated guidance on BMV in May 2018, after much anticipation following the release of the draft in 2013. It is now an authoritative document that the bioanalytical professionals need to incorporate into their standard operating procedures. The good news is that this document does not make drastic changes in the already available guidance from FDA and other global regulatory agencies, but provides a progression in the field due to advancements in science.
The guidance is equally applicable to chromatographic and ligand binding assays covering both the chemical and biological drugs. But to understand how you can apply the recommendations of this standard and avoid confusion on various standards related to same subject ( ex- EMA guidance) an in-depth understanding of these topics would be helpful.
Attend this webinar to understand the core principles, parameters and specifications for bioanalysis provided in the new FDA guidance for method development, validation and sample analysis using chromatographic and ligand binding technologies. The new additional topics on the analysis of endogenous compounds and biomarkers, learn in greater details the method development and report writing. The aim of the webinar is to provide a comprehensive understanding of the existing and new requirements.
Areas Covered in the Webinar:
Core principles, parameters and specifications for bioanalysis provided in the new FDA guidance for method development, validation and sample analysis using chromatographic and ligand binding technologies
Comparison of the new guidance with the first FDA guidance
What remains unchanged
What has changed
New ideas and topics introduced in the new guidance
Comparison of the new FDA guidance with the other major global guidance, e.g. from EMA
Where the guidance have similarities
Any major conflicts and how do we deal with them?
The FDA issued the latest updated guidance on BMV in May 2018, after much anticipation following the release of the draft in 2013. It is now an authoritative document that the bioanalytical professionals need to incorporate into their standard operating procedures. The good news is that this document does not make drastic changes in the already available guidance from FDA and other global regulatory agencies, but provides a progression in the field due to advancements in science.
The guidance is equally applicable to chromatographic and ligand binding assays covering both the chemical and biological drugs. But to understand how you can apply the recommendations of this standard and avoid confusion on various standards related to same subject ( ex- EMA guidance) an in-depth understanding of these topics would be helpful.
Attend this webinar to understand the core principles, parameters and specifications for bioanalysis provided in the new FDA guidance for method development, validation and sample analysis using chromatographic and ligand binding technologies. The new additional topics on the analysis of endogenous compounds and biomarkers, learn in greater details the method development and report writing. The aim of the webinar is to provide a comprehensive understanding of the existing and new requirements.
Areas Covered in the Webinar:
Core principles, parameters and specifications for bioanalysis provided in the new FDA guidance for method development, validation and sample analysis using chromatographic and ligand binding technologies
Comparison of the new guidance with the first FDA guidance
What remains unchanged
What has changed
New ideas and topics introduced in the new guidance
Comparison of the new FDA guidance with the other major global guidance, e.g. from EMA
Where the guidance have similarities
Any major conflicts and how do we deal with them?
